The latest price target for Alterity Therapeutics (NASDAQ:ATHE) was reported by Benchmark on March 7, 2024. The analyst firm set a price target for $4.00 expecting ATHE to rise to within 12 months (a possible 220.00% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Alterity Therapeutics (NASDAQ:ATHE) was provided by Benchmark, and Alterity Therapeutics reiterated their speculative buy rating.

There is no last upgrade for Alterity Therapeutics

There is no last downgrade for Alterity Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alterity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alterity Therapeutics was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.

While ratings are subjective and will change, the latest Alterity Therapeutics (ATHE) rating was a reiterated with a price target of $0.00 to $4.00. The current price Alterity Therapeutics (ATHE) is trading at is $1.25, which is within the analyst’s predicted range.